Prostate treatment fails to cut hip fracture risk
Treating benign prostatic hyperplasia with 5-? reductase inhibitors does not increase hip fracture risk, a large US study reports.
In the first long-term study of finasteride and bone health, analysis of data from 7,000 men over the age of 45 who had a hip fracture and an equal number of controls found 36% of cases and 35% and controls had a diagnosis of BPH.
Among the 250 patients who had received finasteride, the odds ratio of hip fracture associated with the drug was 0.77 (95% CI, 0.59-1.00; P = .04) and there was no suggestion of a dose-response relationship.